2016
Palliative Care for Pancreatic and Periampullary Cancer
Perone JA, Riall TS, Olino K. Palliative Care for Pancreatic and Periampullary Cancer. Surgical Clinics Of North America 2016, 96: 1415-1430. PMID: 27865285, PMCID: PMC5119929, DOI: 10.1016/j.suc.2016.07.012.Peer-Reviewed Original ResearchConceptsMost patientsPalliative careGastric outlet obstructionRelief of painPancreatic cancer patientsAdvanced diseaseLocalized diseaseMultimodality therapyCeliac plexusOutlet obstructionPeriampullary cancerObstructive jaundiceCancer patientsPancreatic cancerPalliative techniquesPatientsCommon endpointCancerDiseaseReliefCareCare triangleFamily goalsJaundicePainLonger Course of Induction Chemotherapy Followed by Chemoradiation Favors Better Survival Outcomes for Patients With Locally Advanced Pancreatic Cancer
Faisal F, Tsai HL, Blackford A, Olino K, Xia C, De Jesus-Acosta A, Le DT, Cosgrove D, Azad N, Rasheed Z, Diaz LA, Donehower R, Laheru D, Hruban RH, Fishman EK, Edil BH, Schulick R, Wolfgang C, Herman J, Zheng L. Longer Course of Induction Chemotherapy Followed by Chemoradiation Favors Better Survival Outcomes for Patients With Locally Advanced Pancreatic Cancer. American Journal Of Clinical Oncology 2016, 39: 18-26. PMID: 24351782, PMCID: PMC4061284, DOI: 10.1097/coc.0000000000000022.Peer-Reviewed Original ResearchMeSH KeywordsAdultAge FactorsAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsCapecitabineChemoradiotherapyCohort StudiesDeoxycytidineDisease-Free SurvivalFemaleFluorouracilGemcitabineHumansInduction ChemotherapyMaleMiddle AgedNeoplasm StagingPancreatic NeoplasmsProportional Hazards ModelsRetrospective StudiesSex FactorsTime FactorsTreatment OutcomeConceptsAdvanced pancreatic cancerCycles of chemotherapyOverall survivalInduction chemotherapyPancreatic cancerMedian overall survivalRole of chemotherapyTreatment of LAPCUnresectable stage 3Better survival outcomesBetter overall survivalCombination of chemotherapyJohns Hopkins HospitalSensitization of tumorsConsolidative chemoradiationSubsequent chemoradiationCombination chemotherapyCumulative incidenceProspective studySurvival outcomesStandard treatmentDisease progressionChemoradiationRetrospective analysisChemotherapy
2012
Clinicopathological Characteristics and Molecular Analyses of Multifocal Intraductal Papillary Mucinous Neoplasms of the Pancreas
Matthaei H, Norris AL, Tsiatis AC, Olino K, Hong SM, dal Molin M, Goggins MG, Canto M, Horton KM, Jackson KD, Capelli P, Zamboni G, Bortesi L, Furukawa T, Egawa S, Ishida M, Ottomo S, Unno M, Motoi F, Wolfgang CL, Edil BH, Cameron JL, Eshleman JR, Schulick RD, Maitra A, Hruban RH. Clinicopathological Characteristics and Molecular Analyses of Multifocal Intraductal Papillary Mucinous Neoplasms of the Pancreas. Annals Of Surgery 2012, 255: 326-333. PMID: 22167000, PMCID: PMC3534752, DOI: 10.1097/sla.0b013e3182378a18.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinoma, MucinousAgedAged, 80 and overCarcinoma, Pancreatic DuctalCarcinoma, PapillaryClone CellsFemaleHumansLaser Capture MicrodissectionLoss of HeterozygosityMaleMiddle AgedMutationNeoplasms, Multiple PrimaryNeoplasms, Second PrimaryPancreatic NeoplasmsProto-Oncogene ProteinsProto-Oncogene Proteins p21(ras)Ras ProteinsRetrospective StudiesSequence Analysis, DNAConceptsMultifocal intraductal papillary mucinous neoplasmsIntraductal papillary mucinous neoplasmPapillary mucinous neoplasmMucinous neoplasmsClinicopathologic featuresPancreatic cancerClonal relationshipBranch duct lesionsCystic precursor lesionsFamilial pancreatic cancerKRAS gene mutationsIntermediate dysplasiaIndependent genetic alterationsDuct lesionsClinicopathological characteristicsInvasive cancerPrecursor lesionsPartial pancreatectomyPatientsNeoplasmsIntermediate gradeGene mutationsCancerGenetic alterationsMolecular analysis
2011
Tyrosine 23 Phosphorylation-Dependent Cell-Surface Localization of Annexin A2 Is Required for Invasion and Metastases of Pancreatic Cancer
Zheng L, Foley K, Huang L, Leubner A, Mo G, Olino K, Edil BH, Mizuma M, Sharma R, Le DT, Anders RA, Illei PB, Van Eyk JE, Maitra A, Laheru D, Jaffee EM. Tyrosine 23 Phosphorylation-Dependent Cell-Surface Localization of Annexin A2 Is Required for Invasion and Metastases of Pancreatic Cancer. PLOS ONE 2011, 6: e19390. PMID: 21572519, PMCID: PMC3084841, DOI: 10.1371/journal.pone.0019390.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsAnnexin A2Antibodies, MonoclonalAntigens, NeoplasmBiomarkers, TumorBlotting, WesternCancer VaccinesCell Line, TumorCell MembraneCell MovementDisease-Free SurvivalEpithelial-Mesenchymal TransitionFemaleHumansLiverMiceMice, Inbred C57BLNeoplasm InvasivenessNeoplasm MetastasisNeoplasms, ExperimentalPancreatic NeoplasmsPhosphorylationRNA InterferenceTumor Cells, CulturedTyrosineConceptsPancreatic ductal adenocarcinomaAnti-ANXA2 antibodiesPDA metastasisEpithelial-mesenchymal transitionAnnexin A2PDA cellsPost-treatment seraProlongs mouse survivalHigh metastatic potentialCalcium-dependent phospholipid-binding proteinMouse survivalPancreatic cancerDuctal adenocarcinomaEffective therapyProlonged survivalNovel molecular pathwaysANXA2 expressionSerum inhibitsMetastasisPhospholipid-binding proteinEMT processMetastatic potentialAntibody inhibitsPDA developmentNew targets
2009
SMAD4 Gene Mutations Are Associated with Poor Prognosis in Pancreatic Cancer
Blackford A, Serrano OK, Wolfgang CL, Parmigiani G, Jones S, Zhang X, Parsons DW, Lin JC, Leary RJ, Eshleman JR, Goggins M, Jaffee EM, Iacobuzio-Donahue CA, Maitra A, Cameron JL, Olino K, Schulick R, Winter J, Herman JM, Laheru D, Klein AP, Vogelstein B, Kinzler KW, Velculescu VE, Hruban RH. SMAD4 Gene Mutations Are Associated with Poor Prognosis in Pancreatic Cancer. Clinical Cancer Research 2009, 15: 4674-4679. PMID: 19584151, PMCID: PMC2819274, DOI: 10.1158/1078-0432.ccr-09-0227.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinomaAdultAgedAged, 80 and overFemaleGene DeletionHumansKaplan-Meier EstimateMaleMiddle AgedMutationPancreatic NeoplasmsPrognosisProtein Serine-Threonine KinasesReceptor, Transforming Growth Factor-beta Type IIReceptors, Transforming Growth Factor betaSmad4 ProteinTumor Suppressor Protein p53ConceptsPoor prognosisPancreatic cancerLymph node statusShorter overall survivalSMAD4 gene mutationUnderwent pancreaticoduodenectomyOverall survivalMargin statusNode statusTumor sizePatient outcomesPatientsAdenocarcinomaPancreasCancerPrognosisGene mutationsSMAD4 inactivationGene inactivationSomatic mutationsHomozygous deletionMonthsSurvivalGenetic Mutations Associated with Cigarette Smoking in Pancreatic Cancer
Blackford A, Parmigiani G, Kensler TW, Wolfgang C, Jones S, Zhang X, Parsons DW, Lin JC, Leary RJ, Eshleman JR, Goggins M, Jaffee EM, Iacobuzio-Donahue CA, Maitra A, Klein A, Cameron JL, Olino K, Schulick R, Winter J, Vogelstein B, Velculescu VE, Kinzler KW, Hruban RH. Genetic Mutations Associated with Cigarette Smoking in Pancreatic Cancer. Cancer Research 2009, 69: 3681-3688. PMID: 19351817, PMCID: PMC2669837, DOI: 10.1158/0008-5472.can-09-0015.Peer-Reviewed Original ResearchConceptsPancreatic cancerCigarette smokingGenetic Mutations AssociatedSomatic mutationsPancreatic cancer genomeCigarette smokersSmoking accountsPancreatic carcinomaDiscovery screenSmokersCarcinomaSmokingCancerMutations AssociatedMutational patternsAdenocarcinomaDriver genesPancreasCigarettesMore mutationsMutationsNonsynonymous mutationsNonsmokersPrevious studiesIndividuals